Conference Coverage
Latest News
Advertisement
Shorts
0:52
Why TRT Is no longer a blanket denial for cardiac risk
21 hours ago
by
Helen L. Bernie, DO, MPH
1:25
Patient selection for perioperative treatment in high-risk localized prostate cancer
2 days ago
by
Adam B. Weiner, MD(+1 more)
0:58
Heat, plastic, and exposure: What patients should know
6 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
0:52
Vivian Wan, MD, on the value of mapping biopsies for CIS detection
8 days ago
by
Vivian Wan, MD
1:12
FDA testosterone label updates: 2 meaningful changes
9 days ago
by
Helen L. Bernie, DO, MPH
0:36
EV-302 response rates put surgical consolidation in context
12 days ago
by
Betty Wang, MD
0:52
Amy E. Krambeck, MD, outlines anatomic enucleation course
13 days ago
by
Amy E. Krambeck, MD
1:23
Daniel J. George, MD, on the significance of capivasertib for PTEN-deficient mHSPC
14 days ago
by
Daniel J. George, MD
1:43
What it takes to move the needle on urologic patient safety
15 days ago
by
Matthew Nielsen, MD, MS, FACS
0:42
Why patients choose Break Wave over URS
16 days ago
by
Ben H. Chew, MD, MSc
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
The FDA's proposed narrowing of the testosterone therapy prostate cancer contraindication to metastatic disease only reflects current clinical evidence, opening the door to testosterone therapy in appropriately selected men with treated localized prostate cancer or on active surveillance, with shared decision-making and PSA-testosterone co-monitoring as the foundation of responsible care, as Helen L. Bernie, DO, MPH, outlines in this interview.
"Ultimately, integrating robust, disease-specific PROs into routine bladder cancer care represents a key step toward more truly patient-centered management," write the authors.
Interim results from the phase 2 CONVERGE-01 trial showed encouraging antitumor activity and a manageable safety profile with Ac-225 rosopatamab tetraxetan in mCRPC.
Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer.
Atish D. Choudhury, MD, PhD, discusses findings from the A-DREAM / Alliance A032101 trial evaluating treatment interruption following favorable response to combination ADT and ARPI therapy in mHSPC.
The tentative approval spans tablets in 40-mg, 80-mg, 120-mg, and 160-mg strengths.
In this episode of The UroOnc Minute, Adam B. Weiner, MD, is joined by Keyan Salari, MD, PhD, to examine the results of the PROTEUS trial and their implications for managing high-risk localized prostate cancer.
Kevin Koo, MD, MPH, highlights findings from a study evaluating automated kidney stone detection and measurement on CT.
The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline.
In this video, Isaac Y. Kim, MD, PhD, MBA, discusses why immunotherapy may ultimately represent the next major advance in prostate cancer treatment.
Advertisement
The NCCN recommends that clinicians consider using ctDNA-MRD testing to stratify risk and guide the use of adjuvant immunotherapy in patients who have not previously received an immune checkpoint inhibitor.
Break Wave lithotripsy's real-time ultrasound visualization of cavitation and its low-energy resonant frequency delivery mechanistically reduce the risk of renal hematoma and arrhythmia seen with conventional shock wave lithotripsy, while the boundaries of stone size, Hounsfield unit thresholds, and patient anatomy eligible for treatment remain to be defined in commercial practice, according to Ben H. Chew, MD, MSc, FRCSC.
This decision marks the first approval of a PD-1 inhibitor plus antibody-drug conjugate regimen in the EU.
Fred Saad, MD, CQ, FRCS, FCAHS, discusses additional efficacy data from the phase 3 PSMAddition trial, evaluating the addition of 177Lu-PSMA-617 to standard of care ADT plus an ARPI in PMSA+ mHSPC.
Mina M. Fam, MD, discusses the significance of the FDA's recent approval of tebipenem pivoxil for patients with complicated urinary tract infections.
Advertisement
Advertisement
Trending on Urology Times
1
Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC
2
5 urologic oncology headlines you missed in Q2 2026
3
5 benign urology headlines you missed in Q2 2026
4
Helen L. Bernie, DO, MPH, on counseling patients through TRT and prostate cancer uncertainty
5